Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03513588 · ClinicalTrials.gov registry record · Phase 1
2-Week Study In People With Nonalcoholic Fatty Liver Disease
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03513588 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 48 participants.
The verdict
NCT03513588, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
2-week study in people with nonalcoholic fatty liver disease. Study drug at 1 of 2 doses, or placebo, will be given for 14 days. Blood samples, heart monitoring, vital signs, and imaging procedures will be performed.
Interventions
- DRUG Placebo
- DRUG PF-06865571
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2019-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03513588
The ClinicalTrials.gov registry entry for NCT03513588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03513588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03513588 about?
NCT03513588 is a clinical study titled "2-Week Study In People With Nonalcoholic Fatty Liver Disease". 2-week study in people with nonalcoholic fatty liver disease. Study drug at 1 of 2 doses, or placebo, will be given for 14 days. Blood samples, heart monitoring, vital signs, and imaging procedures will be performed.
What is the current status of trial NCT03513588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2018-06-21. Estimated completion is 2019-04-04.
What interventions are being tested in trial NCT03513588?
The interventions under investigation include: Placebo (DRUG), PF-06865571 (DRUG).
Who is sponsoring clinical trial NCT03513588?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.